Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lisinopril Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 8/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisinopril Anhydrous SCHEMBL454824 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL29047795 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL1268274 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL31692087 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL542591 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL24062681 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL15680 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL156900 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL7268245 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL18712916 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100029734-A1 | METHODS FOR BREAST CANCER SCREENING AND TREATMENT | ORE PHARMACEUTICALS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2021000-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | Braincells, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885LMNA 3688/4885SMN1; SMN2 138/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885LMNA 2155/4885SMN1; SMN2 907/4885 |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885LMNA 2061/4885SMN1; SMN2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.